T
Tuna Mutis
Researcher at VU University Amsterdam
Publications - 183
Citations - 10283
Tuna Mutis is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Cytotoxic T cell & Antigen. The author has an hindex of 44, co-authored 174 publications receiving 8771 citations. Previous affiliations of Tuna Mutis include Utrecht University & University of Groningen.
Papers
More filters
Journal ArticleDOI
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors
Michel de Weers,Yu-Tzu Tai,Michael S. van der Veer,Joost M. Bakker,Tom Vink,Daniëlle C H Jacobs,Lukas A. Oomen,Matthias Peipp,Thomas Valerius,Jerry W. Slootstra,Tuna Mutis,Wim K. Bleeker,Kenneth C. Anderson,Henk M. Lokhorst,Jan G. J. van de Winkel,Jan G. J. van de Winkel,Paul W. H. I. Parren +16 more
TL;DR: The results show the versatility of daratumumab to effectively kill CD38-expressing tumor cells, including patient MM cells, via diverse cytotoxic mechanisms, and support clinical development of darsatumab for the treatment of CD 38-positive MM tumors.
Journal ArticleDOI
Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik,Jakub Krejcik,Tineke Casneuf,Inger S. Nijhof,Bie Verbist,Jaime Bald,Torben Plesner,Khaja Syed,Kevin Liu,Niels W.C.J. van de Donk,Brendan M. Weiss,Tahamtan Ahmadi,Henk M. Lokhorst,Tuna Mutis,A. Kate Sasser +14 more
TL;DR: Depletion of CD38(+) immunosuppressive cells, which is associated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR clonality, represents possible additional mechanisms of action for daratumumab and deserves further exploration.
Journal ArticleDOI
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia.
W. A. Erik Marijt,Mirjam H.M. Heemskerk,Freke M. Kloosterboer,Els Goulmy,Michel G.D. Kester,Menno A. W. G. van der Hoorn,Simone A. P. van Luxemburg-Heys,Manja Hoogeboom,Tuna Mutis,Jan W. Drijfhout,Jon J. van Rood,Roel Willemze,J. H. Frederik Falkenburg +12 more
TL;DR: HA-1- and HA-2-specific cytotoxic T lymphocytes emerging in the blood of patients after DLI demonstrate graft-versus-leukemia or myeloma reactivity resulting in a durable remission, implying that in vitro generated HA- 1- and HLA-A2/HA-2 peptide tetrameric complexes could be used as adoptive immunotherapy to treat hematological malignances relapsing after alloSCT.
Journal ArticleDOI
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk,Sandra Verploegen,Marijn Bögels,M. van Egmond,J. J. L. van Bueren,Tuna Mutis,Richard W.J. Groen,E.C.W. Breij,Anton C.M. Martens,Wim K. Bleeker,Paul W. H. I. Parren +10 more
TL;DR: It is demonstrated that phagocytosis is a fast, potent and clinically relevant mechanism of action that may contribute to the therapeutic activity of DARA in multiple myeloma and potentially other hematological tumors.
Journal ArticleDOI
Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization
Jorg van Loosdregt,Yvonne Vercoulen,Teun Guichelaar,Yoony Y.J. Gent,Jeffrey M. Beekman,Olivier van Beekum,Arjan B. Brenkman,DirkJan Hijnen,Tuna Mutis,Eric Kalkhoven,Berent J. Prakken,Paul J. Coffer +11 more
TL;DR: Modulation of the acetylation state of Foxp3 provides a novel molecular mechanism for assuring rapid temporal control ofFoxp3 levels in T cells, thereby regulating Treg numbers and functionality and could provide a new therapeutic strategy to control inappropriate (auto)immune responses.